Company Overview
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology. TriKE™ therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
Recent News
GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer
Stock Overview
Symbol
GTBP
Exchange
Nasdaq
Market Cap
97.01m
Last Price
$4.54
52-Week Range
$0.26 - $7.10
03/08/2021 04:00 PM EST